Regulation of Fgf15 expression in the intestine by glucocorticoid receptor
AffiliationUniv Arizona, Coll Pharm, Dept Pharmacol & Toxicol
MetadataShow full item record
PublisherSPANDIDOS PUBL LTD
CitationJia, K., Zhang, D., Jia, Q., & Zhang, Q. (2019). Regulation of Fgf15 expression in the intestine by glucocorticoid receptor. Molecular Medicine Reports, 19, 2953-2959. https://doi.org/10.3892/mmr.2019.9915
JournalMOLECULAR MEDICINE REPORTS
RightsCOPYRIGHT 2019 Spandidos Publications
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at firstname.lastname@example.org.
AbstractFibroblast growth factor 15 (FGF15) was previously identified to be highly expressed in the ileum and functions as an endocrine factor to regulate bile acid synthesis in the liver. FGF15 targets its receptor fibroblast growth factor receptor 4 in the liver and serves important roles in energy metabolism, including bile acid homeostasis, glucose metabolism and protein synthesis. The expression of FGF15 is known to be regulated by the transcription factor farnesoid X receptor (FXR). In the present study, reverse transcription-quantitative polymerase chain reaction was used for measuring Fgf15 expression from the animal and tissue culture experiments, and it was identified that dexamethasone, a drug widely used in anti-inflammation therapy, and a classical inducer of glucocorticoid receptor (GR)- and pregnane X receptor (PXR)-target genes, may downregulate Fgf15 expression in the ileum. GR was identified to be highly expressed in the ileum by western blot analysis. Furthermore, it was demonstrated that the downregulation of Fgf15 by dexamethasone is due to the repression of ileal FXR activity via GR; however, not PXR, in the ileum. The present results provide insight for a better understanding of the adverse effects associated with dexamethasone therapy.
Note6 month embargo; published online: 30 January 2019
VersionFinal published version
SponsorsNational Institute of General Medical Sciences [GM082978]; Chinese National Nature Sciences Foundation ; Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry; Fujian Provincial Nature Science Foundation [2015J05052]; Fujian Agriculture and Forestry University Science Fund for Distinguished Young Scholars [xjq201629]; (Fuzhou, China)
- Alterations in Enterohepatic Fgf15 Signaling and Changes in Bile Acid Composition Depend on Localization of Murine Intestinal Inflammation.
- Authors: Rau M, Stieger B, Monte MJ, Schmitt J, Jahn D, Frey-Wagner I, Raselli T, Marin JJ, Müllhaupt B, Rogler G, Geier A
- Issue date: 2016 Oct
- Interaction of glucocorticoids with FXR/FGF19/FGF21-mediated ileum-liver crosstalk.
- Authors: Al-Aqil FA, Monte MJ, Peleteiro-Vigil A, Briz O, Rosales R, González R, Aranda CJ, Ocón B, Uriarte I, de Medina FS, Martinez-Augustín O, Avila MA, Marín JJG, Romero MR
- Issue date: 2018 Sep
- The cholesterol-raising factor from coffee beans, cafestol, as an agonist ligand for the farnesoid and pregnane X receptors.
- Authors: Ricketts ML, Boekschoten MV, Kreeft AJ, Hooiveld GJ, Moen CJ, Müller M, Frants RR, Kasanmoentalib S, Post SM, Princen HM, Porter JG, Katan MB, Hofker MH, Moore DD
- Issue date: 2007 Jul
- Pregnane X receptor (PXR) deficiency improves high fat diet-induced obesity via induction of fibroblast growth factor 15 (FGF15) expression.
- Authors: Zhao LY, Xu JY, Shi Z, Englert NA, Zhang SY
- Issue date: 2017 Oct 15
- Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15.
- Authors: Zhou M, Luo J, Chen M, Yang H, Learned RM, DePaoli AM, Tian H, Ling L
- Issue date: 2017 Jun